Literature DB >> 28660401

Individual Bayesian Information Matrix for Predicting Estimation Error and Shrinkage of Individual Parameters Accounting for Data Below the Limit of Quantification.

Thi Huyen Tram Nguyen1, Thu Thuy Nguyen2, France Mentré1.   

Abstract

PURPOSE: In mixed models, the relative standard errors (RSE) and shrinkage of individual parameters can be predicted from the individual Bayesian information matrix (MBF). We proposed an approach accounting for data below the limit of quantification (LOQ) in MBF.
METHODS: MBF is the sum of the expectation of the individual Fisher information (MIF) which can be evaluated by First-Order linearization and the inverse of random effect variance. We expressed the individual information as a weighted sum of predicted MIF for every possible design composing of measurements above and/or below LOQ. When evaluating MIF, we derived the likelihood expressed as the product of the likelihood of observed data and the probability for data to be below LOQ. The relevance of RSE and shrinkage predicted by MBF in absence or presence of data below LOQ were evaluated by simulations, using a pharmacokinetic/viral kinetic model defined by differential equations.
RESULTS: Simulations showed good agreement between predicted and observed RSE and shrinkage in absence or presence of data below LOQ. We found that RSE and shrinkage increased with sparser designs and with data below LOQ.
CONCLUSIONS: The proposed method based on MBF adequately predicted individual RSE and shrinkage, allowing for evaluation of a large number of scenarios without extensive simulations.

Entities:  

Keywords:  Bayesian fisher information matrix; data below the limit of quantification; nonlinear mixed effect models; optimal design; shrinkage

Mesh:

Year:  2017        PMID: 28660401     DOI: 10.1007/s11095-017-2217-0

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  25 in total

1.  Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions.

Authors:  Radojka M Savic; Mats O Karlsson
Journal:  AAPS J       Date:  2009-08-01       Impact factor: 4.009

2.  Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0.

Authors:  Caroline Bazzoli; Sylvie Retout; France Mentré
Journal:  Comput Methods Programs Biomed       Date:  2009-11-04       Impact factor: 5.428

3.  Optimal sampling times for a drug and its metabolite using SIMCYP(®) simulations as prior information.

Authors:  Cyrielle Dumont; France Mentré; Clare Gaynor; Karl Brendel; Charlotte Gesson; Marylore Chenel
Journal:  Clin Pharmacokinet       Date:  2013-01       Impact factor: 6.447

4.  Shrinkage in nonlinear mixed-effects population models: quantification, influencing factors, and impact.

Authors:  Xu Steven Xu; Min Yuan; Mats O Karlsson; Adrian Dunne; Partha Nandy; An Vermeulen
Journal:  AAPS J       Date:  2012-09-20       Impact factor: 4.009

5.  Extension of NPDE for evaluation of nonlinear mixed effect models in presence of data below the quantification limit with applications to HIV dynamic model.

Authors:  Thi Huyen Tram Nguyen; Emmanuelle Comets; France Mentré
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-08-11       Impact factor: 2.745

6.  Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration.

Authors:  Jeremie Guedj; Alan S Perelson
Journal:  Hepatology       Date:  2011-05-02       Impact factor: 17.425

Review 7.  Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.

Authors:  D Hartwell; J Jones; L Baxter; J Shepherd
Journal:  Health Technol Assess       Date:  2011-04       Impact factor: 4.014

8.  Basic concepts in population modeling, simulation, and model-based drug development.

Authors:  D R Mould; R N Upton
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2012-09-26

9.  Current Use and Developments Needed for Optimal Design in Pharmacometrics: A Study Performed Among DDMoRe's European Federation of Pharmaceutical Industries and Associations Members.

Authors:  F Mentré; M Chenel; E Comets; J Grevel; A Hooker; M O Karlsson; M Lavielle; I Gueorguieva
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-06-05

10.  Estimation of dynamical model parameters taking into account undetectable marker values.

Authors:  Rodolphe Thiébaut; Jérémie Guedj; Hélène Jacqmin-Gadda; Geneviève Chêne; Pascale Trimoulet; Didier Neau; Daniel Commenges
Journal:  BMC Med Res Methodol       Date:  2006-08-01       Impact factor: 4.615

View more
  1 in total

1.  "De-Shrinking" EBEs: The Solution for Bayesian Therapeutic Drug Monitoring.

Authors:  Sarah Baklouti; Peggy Gandia; Didier Concordet
Journal:  Clin Pharmacokinet       Date:  2022-02-04       Impact factor: 5.577

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.